Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Moreau P

Open source

DOI: 10.1080/14796694.2026.2683336
Published: 2026 Jun
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2683336,
  title = {Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.},
  author = {Yong K and Martin T and Dimopoulos MA and Mikhael J and Capra M and Facon T and Hajek R and Špička I and Baker R and Kim K and Martinez G and Min CK and Pour L and Leleu X and Oriol A and Koh Y and Suzuki K and Casca F and Macé S and Moreau P},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2683336},
  url = {https://doi.org/10.1080/14796694.2026.2683336}
}

RIS

TY  - JOUR
TI  - Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.
AU  - Yong K
AU  - Martin T
AU  - Dimopoulos MA
AU  - Mikhael J
AU  - Capra M
AU  - Facon T
AU  - Hajek R
AU  - Špička I
AU  - Baker R
AU  - Kim K
AU  - Martinez G
AU  - Min CK
AU  - Pour L
AU  - Leleu X
AU  - Oriol A
AU  - Koh Y
AU  - Suzuki K
AU  - Casca F
AU  - Macé S
AU  - Moreau P
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2683336
UR  - https://doi.org/10.1080/14796694.2026.2683336
ER  -

APA

K, Y., T, M., MA, D., J, M., M, C., T, F., R, H., I, Š., R, B., K, K., G, M., CK, M., L, P., X, L., A, O., Y, K., K, S., F, C., S, M., & P, M. (2026). Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2683336

Source records

pubmed · retrieved 2026-09-26T05:31:42.055Z